当前位置: X-MOL 学术Cardiovasc. Res. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
RUNX1: an emerging therapeutic target for cardiovascular disease.
Cardiovascular Research ( IF 10.2 ) Pub Date : 2020-03-10 , DOI: 10.1093/cvr/cvaa034
Alexandra Riddell 1 , Martin McBride 1 , Thomas Braun 2 , Stuart A Nicklin 1 , Ewan Cameron 3 , Christopher M Loughrey 1 , Tamara P Martin 1
Affiliation  

Runt-related transcription factor-1 (RUNX1), also known as acute myeloid leukaemia 1 protein (AML1), is a member of the core-binding factor family of transcription factors which modulate cell proliferation, differentiation, and survival in multiple systems. It is a master-regulator transcription factor, which has been implicated in diverse signalling pathways and cellular mechanisms during normal development and disease. RUNX1 is best characterized for its indispensable role for definitive haematopoiesis and its involvement in haematological malignancies. However, more recently RUNX1 has been identified as a key regulator of adverse cardiac remodelling following myocardial infarction. This review discusses the role RUNX1 plays in the heart and highlights its therapeutic potential as a target to limit the progression of adverse cardiac remodelling and heart failure.

中文翻译:

RUNX1:心血管疾病的新兴治疗靶点。

Runt 相关转录因子-1 (RUNX1) 也称为急性髓系白血病 1 蛋白 (AML1),是转录因子核心结合因子家族的成员,可在多个系统中调节细胞增殖、分化和存活。它是一种主调节转录因子,与正常发育和疾病期间的多种信号传导途径和细胞机制有关。RUNX1 的最佳特征是其在确定造血过程中不可或缺的作用及其参与血液恶性肿瘤。然而,最近 RUNX1 已被确定为心肌梗死后不良心脏重塑的关键调节因子。这篇综述讨论了 RUNX1 在心脏中的作用,并强调了其作为限制不良心脏重塑和心力衰竭进展的靶点的治疗潜力。
更新日期:2020-03-10
down
wechat
bug